OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC.

District Court, D. New Jersey·Decided September 26, 2022·No. 2:18-cv-11273·Unknown

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

Civil Action No. 18-11273 (MCA)(LDW) OCCIDENTAL CHEMICAL CORPORATION, SPECIAL MASTER DECISION DENYING IN PART AND GRANTING IN Plaintiff, PART DEFENDANT SMALL PARTIES GROUP DEFENDANTS’ MOTION FOR A v. PROTECTIVE ORDER

21ST CENTURY FOX AMERICA, INC., et al.,

Defendants.

INTRODUCTION This matter comes by way of a motion (the “Motion”) filed by Small Parties Group Defendants (“SPG Defendants”) on April 19, 2022, seeking a protective order regarding depositions of the Cooperating Parties Group (“CPG”) and certain consultants on topics that SPG Defendants assert are overly broad and impermissibly seek testimony concerning privileged and confidential information. On May 3, 2022, Plaintiff, Occidental Chemical Corporation (“OxyChem”) filed opposition to the Motion, asserting that the deposition topics for the CPG and certain consultants seek testimony related to SPG Defendants’ counterclaim and facts surrounding their cooperation with the U.S. Environmental Protection Agency (“EPA”). The Motion is fully briefed by the parties, and therefore, is ripe for a decision by the Special Master. For the reasons set forth herein, the Motion is denied in part and granted in part. BACKGROUND

On December 23, 2021, OxyChem served notices of subpoena seeking Rule 30(b)(6) depositions of the CPG and CPG consultants, AECOM Technology Corporation (“AECOM”), Anchor QEA, DE Maximis, and FTI Consulting (“FTI”), in March, April, and May 2022. On January 4, 2022, OxyChem sent amended deposition notices for AECOM, Anchor QEA, and De Maximis, to take depositions in April 2022 (collectively “Deposition Notices”). The pertinent topics in the Deposition Notices were: FTI Topic 4: All Communications and work relating to the RM10.9 Recommendation, including all Communications with the CPG or any CPG Defendant regarding the RM10.9 Recommendation.

FTI Topic 5: All communications between FTI and any Government Entity relating to the Diamond Alkali Superfund Site.

CPG Topic 4: Allocation(s) among members of the CPG of costs incurred in connection with the Diamond Alkali Superfund Site.

CPG Topic 9: The decision to terminate or cease the 2015 Allocation Process, including Communications among CPG Members and Communications between the CPG and any Person regarding the decision to terminate or cease the 2015 Allocation Process.

CPG Topic 10: The allocation of costs initiated by the CPG in 2015 and the reasons that process did not proceed, including any Communication with members of the CPG regarding the Fourth Amendment to the ARAO.

CPG Topic 11: The Fourth Amendment to the ARAO, including Communications among CPG members regarding the Fourth Amendment to the ARAO.

AECOM Topic 2: Communications between [Consultant] and any Person, including without limitation the CPG, any CPG Defendant, any CPG Consultant, or any Government Entity, relating to work performed by [Consultant] for the CPG relating to the Diamond Alkali Superfund Site, the LPRSA, or any OU4 Order.

On February 11, 2022, the SPG Defendants objected to several of the topics in the notices. Specifically, the SPG Defendants asserted that several of the topics were overbroad and vague, and sought information that was protected by the attorney-client privilege, work product doctrine, and/or constituted protected settlement communications. On April 1, 2022, counsel for OxyChem and liaison counsel for the SPG Defendants participated in a meet-and-confer regarding the Deposition Notices. The parties were not able to reach an amicable resolution.

On April 19, 2022, the SPG Defendants filed the Motion. LEGAL STANDARD

“The purpose of discovery is to uncover facts about the claims and defenses set forth in the pleadings and thus the boundaries of relevance under [Federal Rule of Civil Procedure] 26 depend on the context of each action.” In re Gerber Probiotic Sales Practices Litig., 306 F.R.D. 527, 528 (D.N.J. 2015). To that end, Federal Rule of Civil Procedure 26 provides in pertinent part: Parties may obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case, considering the importance of the issues at stake in the action, the amount in controversy, the parties’ relative access to relevant information, the parties’ resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit.

[FED. R. CIV. P. 26(b)(1).]

“Information within this scope of discovery need not be admissible in evidence to be discoverable.” Id. Courts construe Federal Rule of Civil Procedure 26 “broadly to encompass any matter that bears on, or that reasonably could lead to other matters that could bear on, any issue that is or may be in the case.” Oppenheimer Fund, Inc. v. Sanders, 437 U.S. 340, 351, 98 S. Ct. 2380, 57 L. Ed. 2d 253, 265 (1978); see also Nestle Foods Corp. v. Aetna Cas. & Sur. Co., 135 F.R.D. 101, 104 (D.N.J. 1990) (citation omitted). However, courts have the discretion to determine the scope of discovery. In re Gerber Probiotic Sales Practices Litig., 306 F.R.D. at 528. A “court may issue a protective order to regulate the terms, conditions, time or place of discovery.” Adesanya v. Novartis Pharms. Corp., 2015 U.S. Dist. LEXIS 159712, *5 (D.N.J. Nov. 24, 2015) (citations omitted). Federal Rule of Civil Procedure 26(c)(1) provides in pertinent part: A party or any person from whom discovery is sought may move for a protective order in the court where the action is pending . . . The court may, for good cause, issue an order to protect a party or person from annoyance, embarrassment, oppression, or undue burden or expenses, including . . . (A) forbidding the disclosure or discovery; . . . [or, inter alia, ] (D) forbidding inquiry into certain matters, or limiting the scope of disclosure or discovery to certain matters . . . .

[FED. R. CIV. P. 26(c) (1)(A)-(D).]

Indeed, the objective of Federal Rule of Civil Procedure 26(c) is “to guard against redundant or disproportionate discovery by giving the court authority to reduce the amount of discovery that may be directed to matters that are otherwise proper subjects of inquiry.” Notes of Advisory Committee on 1983 amendments, Note to Subdivision (b); see also In re EthiCare Advisors, Inc., 2020 U.S. Dist. LEXIS 144816, at *6 (D.N.J. Aug. 12, 2020) (stating courts may limit discovery when information sought is not proportional to needs of case considering burden and expense). To that end, the grounds for “limiting discovery reflect the existing practice of many courts in issuing protective orders under Rule 26(c).” Id. The Rule “places the burden of persuasion on the party seeking the protective order.” Cipollone v. Liggett Group, Inc., 785 F.2d 1108, 1121 (3d Cir. 1986). “To overcome the presumption, the party seeking the protective order must show good cause by demonstrating particular need for protection.” Cipollone, 785 F.2d at 1121; see also Glenmede Trust Co. v. Thompson, 56 F.3d 476

Free access — add to your briefcase to read the full text and ask questions with AI

OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC., (D.N.J. 2022).

OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC. (OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Oppenheimer Fund, Inc. v. Sanders
437 U.S. 340 (Supreme Court, 1978)
Upjohn Co. v. United States
449 U.S. 383 (Supreme Court, 1981)
United States v. Richard William Landof
591 F.2d 36 (Ninth Circuit, 1979)
Sheldone v. Pennsylvania Turnpike Commission
104 F. Supp. 2d 511 (W.D. Pennsylvania, 2000)
Alexander v. Federal Bureau of Investigation
186 F.R.D. 137 (District of Columbia, 1998)
Koch Materials Co. v. Shore Slurry Seal, Inc.
208 F.R.D. 109 (D. New Jersey, 2002)
Tri-State Hospital Supply Corp. v. United States
226 F.R.D. 118 (District of Columbia, 2005)
In re Human Tissue Products Liability Litigation
255 F.R.D. 151 (D. New Jersey, 2008)
In re Gerber Probiotic Sales Practices Litigation
306 F.R.D. 527 (D. New Jersey, 2015)
Otsuka Pharmaceutical Co. v. Apotex Corp.
310 F.R.D. 256 (D. New Jersey, 2015)
Cipollone v. Liggett Group, Inc.
785 F.2d 1108 (Third Circuit, 1986)
Leonen v. Johns-Manville
135 F.R.D. 94 (D. New Jersey, 1990)
Nestle Foods Corp. v. Aetna Casualty & Surety Co.
135 F.R.D. 101 (D. New Jersey, 1990)